You are here: Industry Insights > liothyronine

News List

Over £100mn in fines for pharma firms hiking prices of crucial thyroid drug europeanpharmaceuticalreview
July 30, 2021
The Competition and Markets Authority fines Advanz and two others for hiking prices of liothyronine tablets by 1,110 percent in eight years.
Acella Pharmaceuticals Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® americanpharmaceuticalreview
May 07, 2021
Acella Pharmaceuticals, LLC, is voluntarily recalling certain lots of 15-mg, 30-mg, 60-mg, 90-mg and 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.
Zydus Cadila gets US FDA nod for Liothyronine Sodium Tablets expresspharma
January 25, 2021
Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 meg, 25 meg, and 50 meg (US RLD: Cytomel Tablets).
Acella Recalls Two Lots of NP Thyroid Due to Sub Potency americanpharmaceuticalreview
September 27, 2020
Acella Pharmaceuticals is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.
Westminster Pharmaceuticals Issues Recall of Levothyroxine, Liothyronine americanpharmaceuticalreview
August 17, 2018
Westminster Pharmaceuticals is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level.